Sifting Through the BP Data

Article

San Francisco - The majority of current treatments for bullous pemphigoid (BP) are not supported by evidence from solid randomized controlled trials, according to Emory University researcher Seaver L. Soon, M.D.

Related Videos
Related Content

Derm In The News: September 17-23

September 23rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

CeraVe Partners With George Washington University to Expand Residency Training Program

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

September 22nd 2023

Derm In The News: September 17-23

September 23rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

CeraVe Partners With George Washington University to Expand Residency Training Program

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

September 22nd 2023

Derm In The News: September 17-23

September 23rd 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

CeraVe Partners With George Washington University to Expand Residency Training Program

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Frontline Forum Part 4: Improving Basal Cell Carcinoma Management

September 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.